Conexeu Sciences Raises $5M via Crowdfunding, Appoints New CEO to Drive Collagen Regeneration Platform

Conexeu Sciences Inc., the biotechnology company that specializes in tissue regeneration, has completed its $5 million Regulation Crowdfunding financing. Within two weeks, $5 million was raised—the maximum amount a company can raise in a 12-month period. Amidst this ambition, the company has appointed a new CEO—the former CEO of Galderma North America. 

The funds through this financing will be used to accelerate the development and commercialization of Conexeu's CXU collagen platform, a liquid extracellular matrix that mimics the native extracellular matrix architecture, providing cells the biological signals required for healing, not scarring, explained Claudia Chavez-Munoz, co-founder of the company. 

Former Galderma North America CEO Miles Harrison joins Conexeu as president and CEO, succeeding Jeff Sharpe, who transitions to chairman.Courtesy of Conexeu Sciences at Adobe StockAccording to an Oct. 16 press release, this allocation allows the company to hone in and apply this platform to five markets: wound care, veterinary medicine, 3D bioprinting, dental soft tissue repair and medical aesthetics.

After collecting the necessary funds for this next phase of growth, Miles Harrison will be leading as president and CEO of the company, succeeding Jeff Sharpe, the former CEO. Harrison has also been appointed to the company’s board of directors, per a Nov. 3 press release.  

Regulation Crowdfunding financing is a U.S. law that lets eligible businesses raise as much as $5 million from anyone—whether accredited or not—through online investment platforms [1]. Conexeu collected the funds through Equifund, an application for startups and small businesses to raise money for crowdfunding. 

Before his role at Conexeu, Harrison served as president and CEO for Galderma North America. He is also co-founder and CEO of Novaestiq, the company that was acquired by Waldencast in July 2025. He said, “Our CXU collagen platform is positioned as the foundation for regenerative innovation, patented across multiple markets; we are not following trends; we are building a company that we believe will define the future of restoration and renewal and deliver life-changing solutions and a better quality of life to patients and consumers worldwide.”  

His successor, Jeff Sharpe, who transitioned to chairman of the board of Conexeu Sciences said, “[Miles] has a long history of building high-performance organizations and creating shareholder value, whilst leading teams that consistently outpace the market. His vision positions Conexeu to shape the future of human and animal regenerative medicine.” 

 References: 

1- https://www.sec.gov/resources-small-businesses/exempt-offerings/regulation-crowdfunding